VEGFA and hypertensive encephalopathy: 2) Clinical data have not been available on VEGFi and VEGFRi cancer patients with hypertension grading and staging, and the risk of acute cardiovascular events such as hypertensive encephalopathy and cerebral hemorrhage caused by VEGFi and VEGFRi needs to be assessed to further evaluate the clinical role and risk of different VEGF pathway inhibitors.